Case report: Adenosquamous carcinoma of the prostate with greater than 20 month response to multimodal therapy

Adenosquamous carcinoma is an extremely rare and lethal subtype of prostate cancer affecting an estimated 0.03 per million men annually. It has been associated with prior hormone therapy for prostate adenocarcinoma. We present a case of de novo adenosquamous carcinoma of the prostate treated with a...

Descripción completa

Detalles Bibliográficos
Autores principales: Hennessey, Alex, Buller, Dylan, Sama, Shashank, Girard, Eric, Clement, Jessica, Ristau, Benjamin T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2019
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6906645/
https://www.ncbi.nlm.nih.gov/pubmed/31867218
http://dx.doi.org/10.1016/j.eucr.2019.101084
_version_ 1783478385584898048
author Hennessey, Alex
Buller, Dylan
Sama, Shashank
Girard, Eric
Clement, Jessica
Ristau, Benjamin T.
author_facet Hennessey, Alex
Buller, Dylan
Sama, Shashank
Girard, Eric
Clement, Jessica
Ristau, Benjamin T.
author_sort Hennessey, Alex
collection PubMed
description Adenosquamous carcinoma is an extremely rare and lethal subtype of prostate cancer affecting an estimated 0.03 per million men annually. It has been associated with prior hormone therapy for prostate adenocarcinoma. We present a case of de novo adenosquamous carcinoma of the prostate treated with a multimodal approach including surgery, androgen-deprivation therapy, chemotherapy, and radiation.
format Online
Article
Text
id pubmed-6906645
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-69066452019-12-20 Case report: Adenosquamous carcinoma of the prostate with greater than 20 month response to multimodal therapy Hennessey, Alex Buller, Dylan Sama, Shashank Girard, Eric Clement, Jessica Ristau, Benjamin T. Urol Case Rep Oncology Adenosquamous carcinoma is an extremely rare and lethal subtype of prostate cancer affecting an estimated 0.03 per million men annually. It has been associated with prior hormone therapy for prostate adenocarcinoma. We present a case of de novo adenosquamous carcinoma of the prostate treated with a multimodal approach including surgery, androgen-deprivation therapy, chemotherapy, and radiation. Elsevier 2019-12-03 /pmc/articles/PMC6906645/ /pubmed/31867218 http://dx.doi.org/10.1016/j.eucr.2019.101084 Text en © 2019 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Oncology
Hennessey, Alex
Buller, Dylan
Sama, Shashank
Girard, Eric
Clement, Jessica
Ristau, Benjamin T.
Case report: Adenosquamous carcinoma of the prostate with greater than 20 month response to multimodal therapy
title Case report: Adenosquamous carcinoma of the prostate with greater than 20 month response to multimodal therapy
title_full Case report: Adenosquamous carcinoma of the prostate with greater than 20 month response to multimodal therapy
title_fullStr Case report: Adenosquamous carcinoma of the prostate with greater than 20 month response to multimodal therapy
title_full_unstemmed Case report: Adenosquamous carcinoma of the prostate with greater than 20 month response to multimodal therapy
title_short Case report: Adenosquamous carcinoma of the prostate with greater than 20 month response to multimodal therapy
title_sort case report: adenosquamous carcinoma of the prostate with greater than 20 month response to multimodal therapy
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6906645/
https://www.ncbi.nlm.nih.gov/pubmed/31867218
http://dx.doi.org/10.1016/j.eucr.2019.101084
work_keys_str_mv AT hennesseyalex casereportadenosquamouscarcinomaoftheprostatewithgreaterthan20monthresponsetomultimodaltherapy
AT bullerdylan casereportadenosquamouscarcinomaoftheprostatewithgreaterthan20monthresponsetomultimodaltherapy
AT samashashank casereportadenosquamouscarcinomaoftheprostatewithgreaterthan20monthresponsetomultimodaltherapy
AT girarderic casereportadenosquamouscarcinomaoftheprostatewithgreaterthan20monthresponsetomultimodaltherapy
AT clementjessica casereportadenosquamouscarcinomaoftheprostatewithgreaterthan20monthresponsetomultimodaltherapy
AT ristaubenjamint casereportadenosquamouscarcinomaoftheprostatewithgreaterthan20monthresponsetomultimodaltherapy

Ejemplares similares